It is well known that AR signalling is maintained or restored in CRPC despite low serum levels of circulating androgens achieved by ADT.[2] Patients will then receive second‐generation AR inhibitors such as enzalutamide which competitively binds to the AR ligand‐binding domain (LBD), outcompeting dihydrotestosterone and thus inhibiting downstream AR signalling and causing PCa cancer to regress. The gene discussed is AR; the disease is cancer.